Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 17, 2024
Daily News
April 17, 2024
- Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
- Santen’s New China Plant Completed, Poised for 2027 Launch
April 17, 2024
- Jardiance, Ofev Continue to Drive Boehringer’s Global Sales
April 17, 2024
- Nippon Shinyaku Seeks Uptravi Use in Pediatric PAH in Japan
April 17, 2024
- Lagevrio’s Smaller Tablet Version Filed in Japan: MSD
April 17, 2024
- Moderna to File mRNA RSV Vaccine in Japan within 2024: Exec
April 17, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…